Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Low FODMAP diet eases gut troubles in SIBO patients

NCT ID NCT07424313

Symptom relief Sponsor: Warsaw University of Life Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a low FODMAP diet (LFD) can reduce stomach symptoms and improve nutrition in people with small intestinal bacterial overgrowth (SIBO). 51 adults who had finished antibiotic treatment were split into two groups: one followed the LFD, the other ate normally. Researchers tracked symptoms, diet, body measurements, and blood tests to see if the diet made a difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

51 people

The number who actually took part.

Started

Feb 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \> 18 years, * SIBO diagnosed by a doctor based on a hydrogen and methane breath test, * the use of one type of antibiotic at the same dose and for the same period of time. Exclusion Criteria: * BMI \< 18.5 kg/m2, * pregnancy and breastfeeding, * the occurrence of allergies and food intolerances, * previous operations on the digestive tract (except appendectomy and hemorrhoidectomy), * eating disorders, * inflammatory bowel diseases, * celiac disease, * cancer, heart, liver and lung diseases with severe course, as well as neurological or psychiatric diseases, * use of dietary modifications in the last 3 months, * use of antibiotics other than those prescribed by a doctor to treat SIBO in the last 3 months, * implanted stimulators (limitation of body composition measurement)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SIBO are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small intestinal bacterial overgrowth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SIBO Small intestinal bacterial overgrowth Small intestinal bacterial overgrowth syndrome (SIBO)

Contacts and locations

Locations

  • Warsaw University of Life Sciences (WULS-SGGW)

    Warsaw, 02-776, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.